ClinConnect ClinConnect Logo
Search / Trial NCT06088043

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Launched by TAKEDA · Oct 12, 2023

Trial Information

Current as of May 09, 2025

Active, not recruiting

Keywords

Drug Therapy Latitude Psoriasis 1, Latitude Research Program

ClinConnect Summary

This clinical trial is studying a new treatment called TAK-279 for people with moderate to severe plaque psoriasis, which is a skin condition that causes red, scaly patches. The main goal of the trial is to see how effectively TAK-279 reduces these skin plaques compared to a placebo (a treatment that does not contain active medication) and another approved treatment called apremilast. Participants will be part of the study for up to 61 weeks and will receive one of the three treatments.

To be eligible for this trial, participants should have had plaque psoriasis for at least six months and have moderate to severe symptoms. They should also be suitable candidates for other treatments like light therapy or systemic therapy, which affects the whole body. However, people with other types of psoriasis, recent infections, or who have previously used TAK-279 or related treatments will not be included. Overall, participants in this trial can expect regular check-ins and evaluations to monitor their skin condition and any side effects from the treatments.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Plaque psoriasis for at least 6 months.
  • 2. Moderate to severe disease.
  • 3. Candidate for phototherapy or systemic therapy.
  • Exclusion Criteria:
  • 1. Other forms of psoriasis.
  • 2. History of recent infection.
  • 3. Prior exposure to TAK-279 or active comparator.
  • Other protocol defined inclusion/exclusion criteria apply.

About Takeda

Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical organization committed to advancing patient care through innovative therapies. Founded in 1781 and headquartered in Osaka, Japan, Takeda focuses on key therapeutic areas including oncology, gastroenterology, neuroscience, and rare diseases. With a strong emphasis on research and development, Takeda leverages cutting-edge science and technology to deliver transformative medicines that address unmet medical needs. The company is dedicated to sustainability and ethical practices, ensuring that its clinical trials uphold the highest standards of safety and efficacy while fostering collaboration with healthcare professionals and communities worldwide.

Locations

Parkville, Victoria, Australia

Shijiazhuang, Hebei, China

Shinjuku Ku, Tokyo, Japan

Tainan, , Taiwan

Chongqing, Chongqing, China

Jinan, Shandong, China

Wuhan, Hubei, China

Beijing, Beijing, China

Shenyang, Liaoning, China

Guangzhou, Guangdong, China

London, Ontario, Canada

Beijing, Beijing, China

Taipei City, , Taiwan

Kaohsiung City, , Taiwan

New Taipei City, , Taiwan

Fuzhou, Fujian, China

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Yinchuan, Ningxia, China

Hangzhou, Zhejiang, China

Genova, Liguria, Italy

Münster, Nordrhein Westfalen, Germany

Guangzhou, Guangdong, China

Shenzhen, Guangdong, China

Wuhan, Hubei, China

Wonju, , Korea, Republic Of

Shinjuku Ku, Tokyo, Japan

Beijing, Beijing, China

Guangzhou, Guangdong, China

Isehara Shi, Kanagawa, Japan

Krakow, , Poland

Taoyuan City, , Taiwan

Bydgoszcz, , Poland

Warszawa, Mazowieckie, Poland

Xian, Shaanxi, China

Portsmouth, New Hampshire, United States

Warszawa, Mazowieckie, Poland

Lublin, Lubelskie, Poland

San Donato Milanese, Lombardia, Italy

Fountain Valley, California, United States

Jongno Gu, Seoul Teugbyeolsi, Korea, Republic Of

Seoul, Seoul Teugbyeolsi, Korea, Republic Of

Lübeck, Schleswig Holstein, Germany

Henderson, Nevada, United States

Fountain Valley, California, United States

Fremont, California, United States

Hialeah, Florida, United States

Rolling Meadows, Illinois, United States

Indianapolis, Indiana, United States

Troy, Michigan, United States

Warren, Michigan, United States

Bexley, Ohio, United States

Murfreesboro, Tennessee, United States

Portsmouth, New Hampshire, United States

Coral Gables, Florida, United States

Ajax, Ontario, Canada

Barrie, Ontario, Canada

Lódz, Lódzkie, Poland

Bialystok, Podlaskie, Poland

Itabashi Ku, Tokyo, Japan

Phoenix, Arizona, United States

Fort Lauderdale, Florida, United States

Miami, Florida, United States

Ocala, Florida, United States

Marietta, Georgia, United States

Savannah, Georgia, United States

Idaho Falls, Idaho, United States

Charleston, South Carolina, United States

Bellaire, Texas, United States

San Antonio, Texas, United States

Columbia, Maryland, United States

New York, New York, United States

Cary, North Carolina, United States

Surrey, British Columbia, Canada

Etobicoke, Ontario, Canada

Guelph, Ontario, Canada

North Bay, Ontario, Canada

North York, Ontario, Canada

Toronto, Ontario, Canada

Warszawa, Mazowieckie, Poland

East Melbourne, Victoria, Australia

Los Angeles, California, United States

Sacramento, California, United States

Lebanon, New Hampshire, United States

Rozzano, Lombardia, Italy

Kagoshima Shi, Kagosima, Japan

Kumamoto, , Japan

Wroclaw, Dolnoslaskie, Poland

Nadarzyn, Mazowieckie, Poland

Warsaw, Mazowieckie, Poland

Gdansk, Pomorskie, Poland

Gdynia, Pomorskie, Poland

Szczecin, Zachodniopomorskie, Poland

Lodz, , Poland

Blankenfelde Mahlow, Brandenburg, Germany

Gdańsk, Pomorskie, Poland

Poznań, Wielkopolskie, Poland

Idaho Falls, Idaho, United States

Indianapolis, Indiana, United States

Kogarah, New South Wales, Australia

Benowa, Queensland, Australia

Carlton, Victoria, Australia

Parkville, Victoria, Australia

Beijing, Beijing, China

Shanghai, Shanghai, China

Catania, Sicilia, Italy

Firenze, Toscana, Italy

Obihiro Shi, Hokkaidô, Japan

Sapporo Shi, Hokkaidô, Japan

Sapporo Shi, Hokkaidô, Japan

Fukuoka Shi, Hukuoka, Japan

Sumida Ku, Tokyo, Japan

Shimotsuke Shi, Totigi, Japan

Sakai Shi, ôsaka, Japan

Gwangju, Gwangju Gwang'yeogsi, Korea, Republic Of

Bundang Gu, Gyeonggido, Korea, Republic Of

Bundang, Gyeonggido, Korea, Republic Of

Wonju, Ohio, Korea, Republic Of

Gwangjin, Seoul Teugbyeolsi, Korea, Republic Of

Seocho, Seoul Teugbyeolsi, Korea, Republic Of

Warsaw, Mazowieckie, Poland

Warszawa, Mazowieckie, Poland

Warszawa, Mazowieckie, Poland

Katowice, Slaskie, Poland

Zhong Zheng Qu, , Taiwan

Parkville, Victoria, Australia

Calgary, Alberta, Canada

Wenzhou, Zhejiang, China

Oldenburg (Oldenburg), Niedersachsen, Germany

L'aquila, Abruzzo, Italy

Napoli, Campania, Italy

Milano, Lombardia, Italy

Seo Gu, Busan Gwangyeogsi, Korea, Republic Of

Daejeon, Daejeon Gwang'yeogsi, Korea, Republic Of

Savannah, Georgia, Korea, Republic Of

Bucheon Si, Gyeonggido, Korea, Republic Of

Bundang Gu Seongnam Si, Gyeonggido, Korea, Republic Of

Gwangjin Gu, Seoul Teugbyeolsi, Korea, Republic Of

Seocho Gu, Seoul Teugbyeolsi, Korea, Republic Of

Warsaw, Mazowieckie, Poland

Hsinchu, , Taiwan

Brisbane, Queensland, Australia

Nagoya Shi, Aiti, Japan

Seoul, Seoul Teugbyeolsi, Korea, Republic Of

Taipei, , Taiwan

Patients applied

0 patients applied

Trial Officials

Study Director

Study Director

Takeda

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported